Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study

P. Pozzilli, S. Manfrini, R. Buzzetti, E. Lampeter, I. De Leeuw, D. Iafusco, M. Prisco, C. Ionescu-Tirgoviste, S. Kolouskovà, T. Linn, J. Ludvigsson, L. Madácsy, A. Seremak Mrozikiewicz, P. M. Mrozikiewicz, T. Podar, J. Vavrinec, B. Vialettes, N. Visalli, T. Yilmaz, P. D. Browne

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5-35 years), followed-up for a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA1c, blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6%) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA1c and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients.

Original languageEnglish
Pages (from-to)258-264
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume68
Issue number3
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Type 1 Diabetes Mellitus
Multicenter Studies
Insulin
Glucose
Isophane Insulin
Estonia
Spontaneous Remission
Social Adjustment
Romania
Hungary
Czech Republic
Belgium
Poland
Turkey
Sweden
Immunotherapy
Italy
France
Germany
Blood Glucose

Keywords

  • Beta-cell destruction
  • Diabetes therapy
  • Insulin
  • Remission
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Pozzilli, P., Manfrini, S., Buzzetti, R., Lampeter, E., Leeuw, I. D., Iafusco, D., ... Browne, P. D. (2005). Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study. Diabetes Research and Clinical Practice, 68(3), 258-264. https://doi.org/10.1016/j.diabres.2004.10.001

Glucose evaluation trial for remission (GETREM) in type 1 diabetes : A European multicentre study. / Pozzilli, P.; Manfrini, S.; Buzzetti, R.; Lampeter, E.; Leeuw, I. De; Iafusco, D.; Prisco, M.; Ionescu-Tirgoviste, C.; Kolouskovà, S.; Linn, T.; Ludvigsson, J.; Madácsy, L.; Seremak Mrozikiewicz, A.; Mrozikiewicz, P. M.; Podar, T.; Vavrinec, J.; Vialettes, B.; Visalli, N.; Yilmaz, T.; Browne, P. D.

In: Diabetes Research and Clinical Practice, Vol. 68, No. 3, 06.2005, p. 258-264.

Research output: Contribution to journalArticle

Pozzilli, P, Manfrini, S, Buzzetti, R, Lampeter, E, Leeuw, ID, Iafusco, D, Prisco, M, Ionescu-Tirgoviste, C, Kolouskovà, S, Linn, T, Ludvigsson, J, Madácsy, L, Seremak Mrozikiewicz, A, Mrozikiewicz, PM, Podar, T, Vavrinec, J, Vialettes, B, Visalli, N, Yilmaz, T & Browne, PD 2005, 'Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study', Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 258-264. https://doi.org/10.1016/j.diabres.2004.10.001
Pozzilli, P. ; Manfrini, S. ; Buzzetti, R. ; Lampeter, E. ; Leeuw, I. De ; Iafusco, D. ; Prisco, M. ; Ionescu-Tirgoviste, C. ; Kolouskovà, S. ; Linn, T. ; Ludvigsson, J. ; Madácsy, L. ; Seremak Mrozikiewicz, A. ; Mrozikiewicz, P. M. ; Podar, T. ; Vavrinec, J. ; Vialettes, B. ; Visalli, N. ; Yilmaz, T. ; Browne, P. D. / Glucose evaluation trial for remission (GETREM) in type 1 diabetes : A European multicentre study. In: Diabetes Research and Clinical Practice. 2005 ; Vol. 68, No. 3. pp. 258-264.
@article{22176bbfc10b410c941d8cb02591e7e2,
title = "Glucose evaluation trial for remission (GETREM) in type 1 diabetes: A European multicentre study",
abstract = "Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5-35 years), followed-up for a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA1c, blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6{\%}) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA1c and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients.",
keywords = "Beta-cell destruction, Diabetes therapy, Insulin, Remission, Type 1 diabetes",
author = "P. Pozzilli and S. Manfrini and R. Buzzetti and E. Lampeter and Leeuw, {I. De} and D. Iafusco and M. Prisco and C. Ionescu-Tirgoviste and S. Kolouskov{\`a} and T. Linn and J. Ludvigsson and L. Mad{\'a}csy and {Seremak Mrozikiewicz}, A. and Mrozikiewicz, {P. M.} and T. Podar and J. Vavrinec and B. Vialettes and N. Visalli and T. Yilmaz and Browne, {P. D.}",
year = "2005",
month = "6",
doi = "10.1016/j.diabres.2004.10.001",
language = "English",
volume = "68",
pages = "258--264",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Glucose evaluation trial for remission (GETREM) in type 1 diabetes

T2 - A European multicentre study

AU - Pozzilli, P.

AU - Manfrini, S.

AU - Buzzetti, R.

AU - Lampeter, E.

AU - Leeuw, I. De

AU - Iafusco, D.

AU - Prisco, M.

AU - Ionescu-Tirgoviste, C.

AU - Kolouskovà, S.

AU - Linn, T.

AU - Ludvigsson, J.

AU - Madácsy, L.

AU - Seremak Mrozikiewicz, A.

AU - Mrozikiewicz, P. M.

AU - Podar, T.

AU - Vavrinec, J.

AU - Vialettes, B.

AU - Visalli, N.

AU - Yilmaz, T.

AU - Browne, P. D.

PY - 2005/6

Y1 - 2005/6

N2 - Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5-35 years), followed-up for a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA1c, blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6%) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA1c and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients.

AB - Objective: Strict metabolic control during the 1st year of type 1 diabetes is thought to be a key factor for achieving clinical remission. The aims of this study were two-fold: (i) to evaluate the frequency and duration of spontaneous remission (defined according to the parameters issued by the International Diabetic Immunotherapy Group (IDIG)) in a European population of consecutive recent onset type 1 diabetes patients (aged 5-35 years), followed-up for a period of 36 months with a common protocol of intensive insulin therapy and without adjunct immune-intervention; and (ii) to identify the predictive factors for clinical remission. Research design and method: A total of 189 consecutive patients with newly diagnosed type 1 diabetes according to ADA criteria were recruited in participating centres (Belgium, Czech Republic, Estonia, France, Germany, Hungary, Italy, Poland, Romania, Sweden and Turkey) and followed-up for a period of up to 36 months. In all patients, intensive insulin therapy was implemented consisting of three or four injections of regular insulin daily with NPH insulin at bedtime. Adjustment of insulin dose was made according to a common protocol. Various clinical characteristics (age, gender, severity of presentation, etc.), history (presence of diabetic siblings in the family, etc.) and integrated parameters of metabolic control (HbA1c, blood glucose, the total insulin dose at hospital discharge adjusted for body weight) were collected. Results: Twenty-two patients (11.6%) experienced remission. The median duration of remission was 9.6 months and the range was 31 months. There was a wide variation among centres. Logistic regression analysis focused on the centre as the main variable in achieving remission. Conclusion: Remission was shown to be very heterogeneous between centres depending on 'other factors' such as patient care and family awareness of the disease rather than on 'measurable factors' such as sex, age, HbA1c and severity of presentation at diagnosis. Using intensive insulin therapy and optimisation of metabolic control, remission occurred in nearly one out of eight patients.

KW - Beta-cell destruction

KW - Diabetes therapy

KW - Insulin

KW - Remission

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=20144370838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144370838&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2004.10.001

DO - 10.1016/j.diabres.2004.10.001

M3 - Article

C2 - 15936469

AN - SCOPUS:20144370838

VL - 68

SP - 258

EP - 264

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 3

ER -